WASHINGTON – The Senate Judiciary Committee has scheduled a Nov. 30 hearing to discuss pricing policies for the Mylan Pharmaceuticals EpiPen epinephrine injector that led to a $465 million settlement with the government.
Judiciary Committee member Amy Klobuchar was among those who called for the hearing.
The hearing will also focus on the misclassification of EpiPen as a generic, a designation that Klobuchar and others said allowed the company to receive more money from the federal Medicaid program than it should have.
